Veyvondi (vonicog alfa)
- Region
- 🇪🇺 EU
- Active substance
- vonicog alfa
- Company
- Baxalta Innovations GmbH
- Status
- Authorised
- Therapeutic area
- von Willebrand Diseases
- CHMP opinion
- Thu 31 May 2018
- EU approval
- Fri 31 Aug 2018
- Application
- EMEA/H/C/004454
- ATC
- B02BD10
- Official record
- www.ema.europa.eu
Indication
Prevention and treatment of haemorrhage or surgical bleeding in adults (age 18 years and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Veyvondi should not be used in the treatment of Haemophilia A.
Regulatory milestones
No milestones recorded in the last year.
Follow Veyvondi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.